28 November 2024
Dr. Martens plc
('Dr. Martens', 'the Company')
Confirmation of new CEO start date
Further to the Company's previous announcement on 16 April 2024 that Ije Nwokorie would succeed Kenny Wilson as its new Chief Executive Officer before the end of FY25, Dr. Martens is pleased to announce that Ije's appointment will take effect from 6 January 2025. The Company also confirms that Kenny Wilson will step down from the Board on that date. Kenny will remain available to Ije and the wider Global Leadership Team until 31 March 2025 to ensure a smooth handover.
In accordance with the Company's statutory obligations under section 430(2B) Companies Act 2006, details of Kenny Wilson's exit arrangements will be made available on the Company's corporate website, www.drmartensplc.com.
This announcement has been made in accordance with the requirements of paragraph 9.6.12 of the UK Listing Rules. The Company confirms that there is no further information required to be disclosed pursuant to paragraph 9.6.13 of the UK Listing Rules.
Enquiries
Investors and analysts
Bethany Barnes, Director of Investor Relations Bethany.Barnes@drmartens.com +44 7825 187465
Beth Fionda, Investor Relations Manager Beth.Fionda@drmartens.com +44 203 995 2644
Press
H/Advisors Maitland +44 207 379 5151
Katharine Spence +44 7384 535739
Gill Hammond, Director of Communications +44 7384 214248
About Dr. Martens
Dr. Martens is an iconic British brand founded in 1960 in Northamptonshire. Produced originally for workers looking for tough, durable boots, the brand was quickly adopted by diverse youth subcultures and associated musical movements. Dr. Martens has since transcended its working-class roots while still celebrating its proud heritage and, six decades later, "Docs" or "DM's" are worn by people around the world who use them as a symbol of empowerment and their own individual attitude. The Company is a constituent of the FTSE 250 index.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
